Regeneron/Sanofi’s Long-Term Alliances Begin Bearing Fruit

Regeneron’s five-year-old antibody partnership with Sanofi may be expensive, but it is starting to produce some interesting compounds in mid-to-late-stage clinical trials, with positive data to show.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet